Semaglutide is a GLP-1 analogue with an Aib (2-amino isobutyric acid) in position 2 and a C18 chain linked to K20 through a small PEG spacer which was accepted by the FDA in 2018 for the treatment of diabetes as a once weekly treatment and is presently in phase 3 clinical trial for a once daily oral treatment 50,51
Curie A, Touil N, Gaillard S, Galanaud D, Leboucq N, Deschenes G, Morin D, Abad F, Luaute J, Bodenan E, Roche L, Acquaviva C, Vianey-Saban C, Cochat P, Cotton F, Bertholet-Thomas A (2020) Neuropsychological and neuroanatomical phenotype in 17 patients with cystinosis
Start your intake Standard Dose vs Microdose GLP-1: The Simple Difference The easiest way to understand the difference is this: standard-dose semaglutide or tirzepatide is usually selected when the primary goal is meaningful weight loss , while microdose semaglutide or tirzepatide is usually selected when the goal is a gentler entry point, lower medication exposure, appetite support, craving control, or improved tolerability
Its not about a temporary fix
At the adipose tissue level, the combined GIP and GLP-1 agonism reduces M1 macrophage infiltration and pro-inflammatory cytokines such as leptin, increases adiponectin, and enhances insulin sensitivity, thereby improving adipocyte dysfunction.39 GIP additionally increases the storage capacity of adipose tissue, which lowers the likelihood of ectopic fat deposition and reduces the extent of visceral fat.1,5,39 Furthermore, it has demonstrated neuroprotective effects and promotes bone formation1 (Table 2)
Because saliva is your mouth's natural defense systemresponsible for neutralizing plaque acids and washing away food particlesa lack of it allows bacteria to multiply rapidly, leading to accelerated decay and enamel erosion